You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

103 Results
Guidelines and Advice
Status: Current
ID: ES PET 16
Version: 2
Apr 2024
Drug
Other Name(s): Leukeran®
Nov 2024
Drug
Nov 2024
Drug
Other Name(s): Xeloda®
Jul 2024
Drug
Other Name(s): Leustatin®
Nov 2024
Drug
Other Name(s): Jevtana®
Nov 2024
Drug
Other Name(s): Zykadia™
Nov 2024
Drug
Other Name(s): Cotellic™
Nov 2024
Regimen
Intent: Adjuvant
Funding:
New Drug Funding Program
    Trastuzumab (Biosimilar) - Adjuvant Treatment for Breast Cancer
Jan 2024
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal, 
Small bowel and appendix
Intent: Adjuvant, Palliative
Funding:
ODB - General Benefit
    capecitabine
Jul 2024
Regimen
Cancer Type:
Gastrointestinal, 
Neuroendocrine (GI)
Intent: Palliative
Jun 2024
Regimen
Cancer Type:
Breast, 
Central Nervous System, 
Gastrointestinal, 
Colorectal, 
Esophagus, 
Gastric / Stomach, 
Hepatobiliary / Liver / Bile Duct, 
Pancreas, 
Genitourinary, 
Bladder / Urothelial, 
Prostate, 
Gynecologic, 
Cervix, 
Endometrial, 
Ovary, 
Head and Neck, 
Lung, 
Small Cell
Intent: Palliative
Mar 2018

Pages